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Amorphous magnesium-substituted calcium phosphate (AMCP) nanoparticles (75-150 nm) form constitutively in large numbers in the
mammalian gut. Collective evidence indicates that they trap and deliver luminal macromolecules to mucosal antigen presenting cells (APCs)
and facilitate gut immune homeostasis. Here, we report on a synthetic mimetic of the endogenous AMCP and show that it has marked
capacity to trap macromolecules during formation. Macromolecular capture into AMCP involved incorporation as shown by STEM
tomography of the synthetic AMCP particle with 5 nm ultra-fine iron (III) oxohydroxide. In vitro, organic cargo-loaded synthetic AMCP
was taken up by APCs and tracked to lysosomal compartments. The AMCP itself did not regulate any gene, or modify any gene regulation
by its cargo, based upon whole genome transcriptomic analyses. We conclude that synthetic AMCP can efficiently trap macromolecules and
deliver them to APCs in a silent fashion, and may thus represent a new platform for antigen delivery.
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1549-9634/© 2016 The Author(s). Published by Elsevier Inc. This is an open accessBio-mineralization is a well conserved physiological phe-
nomenon that occurs in most life forms (bacteria, diatoms,
plants, animals and humans)1–5 and is usually restricted to
specialized tissues (e.g. bone, teeth and otoconia) for the
formation of calcium-based minerals. In mammals, calcium
phosphates are major biominerals and, depending on the tissues
involved, may vary in structure from amorphous calcium
phosphate (ACP) to fully crystalline forms (i.e. apatite). Due to
its low toxicity but ready turnover, potential therapeutic roles for
ACP are multiple, ranging from bio-materials,6 such as in
dentistry,7 through to drug delivery,8,9 such as in vaccination.10
However, ACP is notoriously unstable and its in vivo ‘lifetime’ is
determined not only by environmental factors such as pH,
viscosity, ionic strength and temperature11–13 but also by its own
structure, especially the incorporation of other ions or molecules
(for e.g. fetuin). Boskey & Posner14 studied the kinetics of ACP
conversion and found that substitution of Ca ions in ACP by Mgarticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Sizing andTEMmorphology of syntheticAMCPnanomineral from cell culturemedium: (A-B) Nanoparticle tracking analyses of syntheticAMCPparticles
that were prepared in the presence of bovine serum albumin (BSA) with (red columns) and without bacterial peptidoglycan (sPg; black columns), either (A) in cell
culturemedium (37 °C) immediately after suspension or (B) following 3 h incubation (37 °C) in cell culture medium. Size distributions are shown as average of three
independent experiments and are displayed as cumulative particle number (E6/ml) per size interval (i.e. every 10 nm). Supplementary Table 1 provides additional
data. (C-D) Morphologic characterization of the above particles by TEM after 1 h incubation of the particles in cell culture medium at 37 °C. Scale bars: 100 nm.
Detailed STEM analysis of the precipitated and washed powder prior to addition to cell culture medium is shown in Figure 2. (E) Energy optimized structure of
Mg-substituted calcium phosphate cluster, which represents a precursor to the larger particles. The central Mg substitution is in the most favorable position as
calculated by Density Functional Theory. The composition of the cluster reflects analytical results of the larger particles by X-ray microanalysis. Hydrogen was
included for charge compensation. Calcium is shown in green, oxygen in red, phosphorus in purple, magnesium in yellow and hydrogen in pink.
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has since been confirmed by others.15,16 Interestingly, we reported
that in the human andmurine gastrointestinal tract, there is extensive
constitutive (i.e. natural, physiological) formation of porous
amorphous magnesium-substituted calcium phosphate (AMCP)
nanoparticles, typically 75-150 nm in diameter.17 These
luminally-formed AMCP nanominerals are found co-associated
with macromolecules such as bacterial peptidoglycan and dietary
protein in mucosal antigen presenting cells (APCs).17
These findings with endogenousAMCP imply that the particles
form in the gut lumen, trapping luminal macromolecules in the
process, and then chaperone their cargo to specialized APCs
thereby facilitating cross-talk between the lumen and intestinal
tissue.17 The physiological and biological relevance of this
constitutive self-assembly of nanoparticles and their ‘cargo
shuttling’ function is currently not fully understood but generation
of this knowledge would be greatly facilitated by the synthesis of
in vitro counterparts such that their properties can be scrutinized.
Here we therefore set out to reproduce the exact form of these
entities and, in particular, to test whether the presence of
macromolecules (e.g., proteins and bacterial antigens) and ions
(e.g., magnesium) would affect the phase, structural properties
and stability of the resulting amorphous calcium phosphates.
Under carefully controlled conditions, we demonstrated that the
synthetic mimetics of the endogenous gastrointestinal nanomin-
eral generated amorphous magnesium-substituted calcium phos-
phate nanoparticles (synthetic AMCP) of the right size and phase
with versatile macromolecule-incorporation properties similar to
their in vivo counterparts. We next considered synthetic AMCPinteractions with immune cells at both the gene and protein level.
Particularly, we observed that cargo-containing AMCP nano-
particles were readily taken up by peripheral blood antigen
presenting cells, trafficked to lysosomal compartments and
delivered their cargo in a ‘silent’ fashion. The synthetic mimetics
of the AMCP nanomineral, as described herein, may therefore
have valuable properties in drug delivery given that the material
does not appear to influence outcomes as may be expected with
conventional particle-cargo targeting of cells.18Methods
Synthesis of mimetics of endogenous calcium phosphate with
organic and inorganic macromolecules
Synthetic AMCP particles were prepared using a modified
protocol of Boskey and Posner.14 The modification consisted of the
addition of extra magnesium and protein (bovine serum albumin,
BSA) to enhance phase stability and precipitation in the presence or
absence of, mainly, the microbial associated molecular pattern
peptidoglycan (Pg) to mimic in vivo organic (bacterial) intestinal
components. Exact protocols for each of the combinations
investigated are given in the supplementary methods (Appendix A).
Physico-chemical characterization of synthetic AMCP particles
Size measurement and structural morphology
Following synthesis, hydrodynamic sizes of the AMCP
particles were investigated by nanoparticle tracking analysis
while structural morphology was addressed by transmission
Table 1
Physico-chemical characteristics of synthetic AMCP nanoparticles after synthesis and in cell culture conditions.
Organic content (μg/mg; n = 5-9 ± SD) Ca/P (n = 3 ± SD) ζ potential (n = 3-5 ± SD)
Synthesis AMCP BSA 103.92 ± 17.01 1.29 ± 0.012 -13.22 ± 0.76
AMCP/sPg BSA 86.74 ± 15.37
sPg 10.23 ± 4.46
1.30 ± 0.017 -13.06 ± 0.31
Cell culture conditions t0 AMCP N/A 1.23 ± 0.026 -12.14 ± 0.49
AMCP/sPg N/A 1.29 ± 0.056 -12.97 ± 1.49
Cell culture conditions t3 AMCP N/A 1.29 ± 0.01 N/A
AMCP/sPg N/A 1.31 ± 0.06 N/A
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further investigated using tomography experiments based on
high-angle annular dark-field (HAADF) imaging in the scanning
transmission electron microscopy (STEM) mode.
Elemental composition
Synthetic AMCP particles were dissolved in 5% HNO3
(Sigma-Aldrich Company Ltd., Dorset, UK) prior to inductively
coupled plasma optical emission spectrometry (ICP-OES) analysis.
Samples were analyzed using the JY2000 ICP-OES (Horiba Jobin
Yvon Ltd., Stanmore, UK) and Ca and P signals were detected at
396.847 nm and 177.440 nm, respectively. Quantification was
performed using external standards (Calibration Standard Solutions
1000 ppm, Fisher Scientific UK Ltd., Leicestershire, UK;
0.5-50 ppm). Total Ca and P were obtained from particle
suspensions collected after synthesis or after dilution in tissue
culture medium (TCM). Background correction was performed
using the Ca and P values obtained from D10 (i.e. the TCM) that
had been subjected to the same treatment as particle suspensions.
The Ca/P molar ratio of particle suspensions was calculated as:
Ca/P = ½CCa=AWCaCP=AWP  where Cx is the background-corrected
concentration of the respective element as measured by ICP-OES
and AWx the atomic weight (i.e., 40.08 for Ca and 30.97 for P).
Determination of zeta potential
Electrophoretic mobility measurements of particle suspensions
were performed by phase analysis light scattering on a Zetasizer
Nano ZS (Malvern,Worcestershire, UK). Electrophoretic mobility
of particles, in an applied field of 8.15 V/cm (effective voltage
49.7 V; electrode spacing 6.1 cm), was then converted into zeta
potentials by Dispersion Technology Software 4.20 using Henry's
equation and the Smoluchowski approximation for aqueousmedia.
Measurements were taken as technical triplicates, and data are
shown as mean of three to five independent experiments.Computational modeling
Small precursor calcium phosphate clusters, representative of
the early stages of particle nucleation, were constructed and
simulated. Posner's cluster,19 (Ca9(PO4)6), is considered to be
the primary particle of amorphous calcium phosphate and the
precursor to the formation of crystalline apatite. This cluster
structure was therefore used for the initial model construction,
but further modified by the removal of one calcium ion and the
addition of two hydrogen ions (for charge compensation) to
reflect the experimentally measured mimetic composition as
obtained through X-ray microanalysis. Analysis of the clusters'geometric structure and stability under magnesium ion
substitution (for calcium ions) in all possible configurations
was carried out. The thermodynamic stability was assessed,
using formation energy analysis. The formation energy of a
single Mg substitution into a calcium phosphate cluster is
given by Eq. (1).
E f ¼ EAMCP− EACP þ μMg−μCa
  ð1Þ
where EAMCP is the energy of the Mg-substituted cluster, EACP
is the energy of the cluster prior to Mg-substitution, μMg is the
chemical potential of magnesium and μCa is the chemical potential
of calcium. Chemical potentials for Mg and Ca were calculated
from the lowest energy sources and sinks, namely magnesium and
calcium metal respectively.
Geometry optimization of the AMCP clusters was carried out
using the plane-wave density functional theory code, CASTEP.20
Convergence testing assigned a kinetic energy cut-off of 430 eV
and sampling of the Brillouin zone was carried out at the gamma
point21 with the clusters placed centrally in a 20Å3 simulation cell.
Ultrasoft pseudopotentials were employed22 along with the
generalized gradient approximation (GGA) and PBE exchange-
correlation functional.23 Convergence tolerances for energy
change, maximum displacement and maximum force were set at
1 × 10−5 eV atom−1, 0.001 Å, and 0.03 eV Å−1 respectively. The
simulation cell lattice parameters remained constrained through-
out. For the substitution of Mg into hydroxyapatite, the lattice
parameters were not constrained. Additionally, a maximum stress
tolerance of 0.05 GPa and a 3 × 3 × 3 k-point grid for sampling of
the Brillouin zone were employed.
Macromolecule trapping properties of synthetic AMCP
AMCP-trapping of macromolecules was assessed by deter-
mining the content of BSA and Pg from re-dissolved nanoparticles
using protein and periodic acid Schiff assays, while incorporation
was demonstrated by STEM tomographic reconstruction of
synthetic AMCP containing electron dense material, namely
ultra-fine iron (III) oxohydroxide.24 Detailed methodology can be
found in Appendix A, supplementary Methods.
Biological properties of synthetic AMCP
Studies with primary human cells and experimental protocols
were approved by the research ethics committees of Cambridge, UK
(reference 03/296) and carried out in accordance with approved
guidelines. The biological properties of ACMP nanoparticles were
examined in peripheral blood mononuclear cells, enriched
Figure 2. STEM characterization of synthetic AMCP nanoparticles: (A) High angle annular dark-field STEM image of synthetic AMCP particle clusters (Scale
bar 20 nm) and (B) example elemental composition by energy dispersive X-ray microanalysis. (C-E) A series of orthoslices of a synthetic AMCP particle (Scale
bar 20 nm) revealing a detailed inner structure (F-I) from the reconstructed volume (F) by means of several orthoslices through the XY plan and (G-I)
transparency views through the YZ, XZ and XY orientations, respectively.
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lysosomal co-localizationwere assessed by flow imaging techniques
while AMCP-induced biological responses were investigated by
looking at ‘toxicity’, ‘inflammasome activation’, IL-1β responses
and whole genome transcriptomic analyses. Full methods are given
in Appendix A, supplementary Methods.
Statistics
Significant differences in experiments looking at the inflamma-
some activation were assessed by a two way ANOVA and
Bonferroni's multiple comparisons test while experiments looking
at cellular uptake, cell viability and surface PD-L1 expressionwere
evaluated using 2 tailed paired t tests. Significance was set as
P b 0.05. For transcriptomic studies, significant differences in
expression were assessed using paired Intensity-Based Moderated
T-statistic (IBMT).25 Genes were defined as significantly changed
when the P value was b0.01.Results
Physico-chemical and structural properties
Following a screen of numerous candidate syntheticmethods, we
found that co-precipitation of a model protein (bovine serum
albumin; BSA) at 500 μg/ml with 17.5 mM Ca2+, 19.5 mM
phosphate and 3.6 mM Mg2+ in pH 8 aqueous buffer enabled the
recovery of a precipitate that, when washed and re-suspended in
tissue culture medium, consisted of disperse AMCP nanoparticles
with a hydrodynamic size distribution (D10-D90) from ~50 to
215 nm, aD50 of ~100 nm and a peak size at about 70 nm (Figure 1
and Table S1). Once re-suspended in tissue culture medium, the
particle size, measured by nanoparticle tracking analysis, remained
stable for at least 3 h (Figure 1 and Table 1). The additional
presence of peptidoglycan (50 μg) during co-precipitation did not
impact these findings (Figure 1 and Table 1).
Morphologically, agglomerates of non-facetted, micro-porous
particles were evident and these were shown to be amorphous by
Table 2
Formation energies of magnesium substitution (substituting for calcium ions)
into an energy optimized amorphous calcium phosphate model, based on a
modified Posner’s Cluster.
Structure Particle Formula Formation Energy (eV)
Unsubstituted primary cluster Ca8(PO4)6H2 –
Ca7Mg(PO4)6H2 -0.463
Ca6Mg2(PO4)6H2 +1.644
Ca5Mg3(PO4)6H2 +2.705
Mg-substituted clusters Ca4Mg4(PO4)6H2 +4.244
Ca3Mg5(PO4)6H2 +7.412
Ca2Mg6(PO4)6H2 +7.902
CaMg7(PO4)6H2 +10.971
Lowest energy Mg-substituted HA HA - Mg +1.747
Substitution of a single Mg ion into a unit cell of hydroxyapatite (HA) is also
presented. Positive formation energies indicate an unfavorable/unstable
structure and negative formation energies a favorable/stable structure.
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(Figure 1, C-D and Figure 2, A). To ensure that the optimal
synthetic composition had been attained, first principles Density
Functional Theory (DFT) modeling of an amorphous calcium
phosphate cluster model (Figure 1, E) based on the anticipated
primary particle, which is termed ‘Posner's Cluster’,19 was
undertaken. Prior to undergoing geometry optimization, the
initial ‘Posner's Cluster’ composition was modified to reflect
the X-ray microanalysis results of the larger particles presented
in Figure 2, B, with a reduction in Ca ion concentration and the
addition of two H ions for charge compensation. Simulations
showed that Mg was most favorable in the central cation
position of the cluster. This optimized model was then used to
interrogate the stability of AMCP with differing Mg (substitut-
ing for Ca) concentrations. As previously reported for bulk
phase amorphous calcium phosphate 7,11,14 the presence of both
Mg2+ ions and protein stabilized the amorphous nanoparticles
and retarded/prevented conversion to crystalline calcium
phosphate (Figure S1). However, formation energy analysis,
which quantitatively assesses the thermodynamic stability of an
elemental or molecular substitution in a structure, clearly
showed that concentrations of Mg greater than that of our
mimetic were thermodynamically unfavorable and that the
optimal Mg concentration (which had a negative formation
energy of −0.463 eV) had already been attained, Table 2.
Furthermore, Mg substitution into the crystalline calcium phosphate
phase hydroxyapatite was shown to be energetically unstable, with a
positive formation energy of +1.747 eV. This demonstrated that at
our synthetic composition, the amorphous phase would retain its
integrity and effectively prevent crystallization.
Consistent with our prior in vivo findings,17 analysis by high
angle annular dark field scanning transmission electron microsco-
py (HAADF-STEM; Figure 2, C-E), and then 3D-reconstruction
of protein-loaded synthetic AMCP clusters (Figure 2, F-I)
confirmed the porous nature of the particles (pore average size of1-3 nm). Under the synthetic conditions described above ~50% of
the 500 μg/ml BSA protein was trapped by AMCP whether
peptidoglycan was present or not (Figure 3, A). About 60% of the
50 μg/ml peptidoglycan was also trapped (Figure 3, A) such that,
overall, the AMCP construct contained 10% protein and 1%
bacterial peptidoglycan by weight (Table 1). The synthetic AMCP
nanoparticles were versatile and non-specific in the trapping of
organic matter since other proteins (e.g., avidin) and molecules
such as bacterial lipopolysaccharide (LPS), soluble starch (a
complex carbohydrate) and retinoic acid (vitamin A-derived
compound) were all efficiently incorporated, from 20% to 90%
of their original solution concentration (Figure 3, B). To facilitate
later work that required the use of fluorescent cargo for cellular
experiments, we also show that fluorescently-labeled macromol-
ecules (Alexa Fluor 555 BSA and Texas Red OVA) were trapped
by AMCP (Figure S2, A). It is noteworthy that the presence of Mg
not only provided stability of the particle's phase but it also promoted
a greater association with proteins than regular amorphous calcium
phosphate free of Mg (i.e. ACP; Figure S2, B-C).
To support the idea that the internal porosity observed by
STEM is a result of the AMCP mineral templating around much
smaller macromolecular components during synthesis, we
undertook further studies with an electron dense macromolecule
to enable visualization by electron microscopy. Synthetic AMCP
nanoparticles were therefore prepared in the presence of
ultra-fine iron (III) oxohydroxide nanoparticles24 (5-10 nm
diameter). Electron microscopy imaging (Figure 3, C-D),
tomographic reconstruction (Figure 3, E-H), models with
increasing transparency views (Figure 3, I-L) all confirmed that
the fine nano-iron particles were densely incorporated within the
synthetic AMCP.
Biological properties
We next sought to investigate, in vitro, whether synthetic
AMCP nanoparticles would modulate cellular responses and we
took a step-wise approach where AMCP uptake, cargo delivery,
toxicity, inflammasome activation and gene expression modu-
lation were investigated.
By means of calcein staining and flow imaging analyses we
confirmed that synthetic AMCP nanoparticles were efficiently
and selectively taken up by APCs in culture, namely CD14+
monocytes from a mixed cell culture of peripheral blood
mononuclear cells (PBMC; Figure 4, A-B, P = 0.01). To then
examine protein carriage by AMCP and delivery into cells, we
used BSA fluorescently tagged with Alexa Fluor 555 to track the
incidence of protein within cells of the monocyte lineage in
conjunction with fluorescently labeled AMCP. Twenty-two
percent (±7; SD) of monocytes within PBMC were positive for
AMCP and identified as calcein positive CD14+ cells. The
addition of fluorescent protein during AMCP synthesis did not
alter the percentage of cells displaying calcein positivity
(Figure 4, C-D). Of this AMCP (calcein) positive fraction of
CD14+ cells, over half were also Alexa Fluor 555 bright indicating
the presence of BSA protein in addition to AMCP (data not
shown). These double positive cells were then further assessed for
the spatial similarity of the 2 fluorescent markers. This analysis
suggested that AMCP and protein fluorescence displayed a high
degree of similarity in 60% (± 7; SD) of the CD14+ cells positive
Figure 3. Trapping of macromolecules by the synthetic AMCP nanomineral: (A) Percentage incorporation, from the original solution, of protein (BSA; left
hand-side and middle column) and bacterial peptidoglycan (sPg, right hand-side column) in synthetic AMCP prepared in the presence of BSA with (black
columns) and without peptidoglycan (white column), and as determined by the Bradford protein and periodic acid Schiff assay, respectively (n = 5-6
experiments ± SD). (B) Overall percentage incorporation of protein (black circles are BSA and red circles are avidin), bacterial fragments (black squares are sPg
and red squares are LPS) and other macromolecules (black triangles are soluble starch and red squares are retinoic acid) in synthetic AMCP. (C-D) TEM of
synthetic AMCP nanoparticles prepared in the presence of iron oxide nanoparticles showing fine nano-iron particles densely incorporated into the AMCP
structure. Scale bars 100 nm and 50 nm respectively. (E-H) STEM-tomography data of synthetic AMCP, containing fine nano-iron particles, from the
reconstructed volume by means of several orthoslices through the XY plane and (F-H) showing individual slices and finally (I-L) the 3D reconstruction in
differing views. The iron oxide nanoparticles are shown in red in I-L.
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low similarity images are shown in Figure 4,G. Overall these data
not only corroborate the association of AMCP with macromole-
cules but also demonstrate carriage and delivery of protein into
CD14+ cells by AMCP as indicated by the co-incidence of the
respective fluorescent markers within cells.
We then used adherent macrophages (differentiated THP-1)
to study AMCP dissolution in real time using live imaging (see
supplementary methods). This showed avid uptake of calcein-
labeled AMCP (Figure 5, B) while no fluorescence could be
observed after incubation with calcein alone (Figure 5, A). In
cells, the count of discrete, punctate green-fluorescent objects
decreased gradually over time (Figure 5, C) and became
undetectable 18 h post-stimulation hence confirming that synthetic
AMCP nanoparticles were dissolved/digested (Figure 5, D;
effect of time P b 0.0001). Loss of calcein fluorescence wasnot observed when calcein solutions were incubated alone
(Figure 5,E), consistent with intracellular dissolution of ‘particulate
calcein’ rather than dye quenching over time (Figure 5, E).
Indeed, since AMCP nanoparticles were transported to CD107+
(LAMP1+ve) lysosomal compartments (Figure 5, F) of peripheral
blood monocytes, the time-dependent decline of the fluorescence is
consistent with intracellular particle digestion in the acidic
environment of endo-lysosomes.26–28
Next we investigated APC responses to protein-loaded
nanomineral AMCP with and without peptidoglycan.
Canonical activation of the inflammasome and IL-1β
production usually require a two-signal process29 but may also
arise from lysosomal disruption preceding cell death which can
be induced, for example, by the gorging of calcium phosphate
nanoparticles.30 To demonstrate the role of synthetic AMCP in
inflammasome activation, blood-derived mononuclear cells were
Figure 4. In vitro uptake of synthetic AMCP nanoparticles and delivery of cargo into cells: (A) Flow cytometric quantitation of cells that have taken up synthetic
calcein-labeled AMCP within the lymphocyte and monocyte gates (n = 3 ± SD). (B) Image Stream analyses of PBMC that were incubated with synthetic
calcein-labeled AMCP displaying the monocyte population that have taken up AMCP (n = 4 ± SD). **P = 0.01 versus vehicle. (C). Example of Image Stream
dot plot from one donor showing gated CD14+ cells positive for the AMCP label calcein, and (D) graph showing the average percentage of CD14+ cells positive
for calcein after 3 h incubation with AMCP particles synthesized with or without Af555 labeled BSA. (E) Example histogram plot of calcein/Af555-BSA
similarity scores of double positive cells for 1 subject after 3 h incubation, showing high and low similarity regions. (F) Pie Chart visualizing percentage of
CD14+ (calcein/Af555 double positive) cells falling within high (yellow) and low (green) similarity regions: data shown are the average of experiments
performed on cells from 3 subjects. (G). Example cell images of calcein/Af555 double positive CD14 cells falling within the high and low similarity gate.
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Figure 5. Uptake, lysosomal delivery and dissolution of synthetic AMCP nanoparticles. PMA-differentiated THP-1 macrophages were incubated with
calcein-labeled AMCP for 3 h and then washed to remove residual AMCP particles. Images were then acquired every 2 h by the Incucyte™. (A-C)
Representative images from the green channel (right hand-side) and overlay images of phase contrast and green fluorescence (left hand-side) that were acquired
one hour-post stimulation with (A) TCM, (B) AMCP and (C) 11 h-post stimulation with AMCP (10× magnification). (D) Particle count, as quantified by the
IncucyteZOOM software, was normalized against cell confluence, and is expressed as percent of values obtained in the first scan. X-axis indicates monitoring
time by live cell imaging post-stimulation, i.e., 0 h represents the first scan (i.e. straight after 3 h stimulation with calcein-labeled AMCP). Data are presented as
mean ± SD (n = 5, obtained from two independent experiments performed in technical replicates). (E) Mean green fluorescence intensity of soluble calcein
added at indicated concentrations to tissue culture medium (acellular environment) and measured by the Incucyte™. Dye quenching was induced by the addition
of 1 mM iron as iron hydroxide adipate tartrate. Data are shown as connecting curves for the mean of technical triplicates from one experiment. (F) Image Stream
summary of internalized synthetic calcein-labeled AMCP in peripheral blood monocytes (left column) that were concomitantly positive for the lysosomal marker
CD107 (Right column; n = 4 ± SD).
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pro-IL1β synthesis, and IL-1β production was measured 21 h
after a 3 h-challenge with synthetic AMCP. Under conditions
where artifactual activation of the inflammasome is avoided,30 it
was evident that synthetic AMCP, in contrast to crude
peptidoglycan (Figure 6, A; P b 0.01) and to some calcium
phosphate crystals,31,32 did not activate the inflammasome
platform as the levels of secreted IL-1β were similar to those
observed for the control (i.e. vehicle alone; Figure 6, A).
Moreover, cellular uptake of synthetic AMCP was innocuous
even under prolonged experimental conditions where particle
gorging may ensue30 (i.e., following 24 h exposure in culture) as
cell viability was not affected in primary cells or THP-1 cells
(P = 0.0003 versus apatitic calcium phosphate-challenged cells;
Figure 6, B).Having observed neither toxicity nor inflammasome activa-
tion by the AMCP nanomineral under the tested conditions, we
next considered what cellular responses did ensue. We looked at
responses across the whole genome and, remarkably, found that
cells challenged with protein-loaded synthetic AMCP nanopar-
ticles displayed exactly the same transcriptomic ‘signature’ to
that of unchallenged cells (Figure 6,C). Since peptidoglycan is the
inferred signaling molecule in the nanomineral-antigen-
peptidoglycan pathway, we next sought how synthetic AMCP
nanoparticles, loaded with both protein and peptidoglycan,
affected peptidoglycan ‘signaling’. Masking (i.e., down regulation
of the cell's sensitivity to peptidoglycan) and enhancing
recognition were both possibilities so, again, we used whole
genome transcriptomics as a read-out. Whether delivered in
soluble form or as cargo within the synthetic AMCP nanoparticles,
Figure 6. In vitro gene and cellular responses to AMCP nanoparticles: (A) Lack of inflammasome activation by synthetic AMCP as measured by IL-1β secretion
following LPS pre-stimulation (10 ng/ml) and subsequent challenge with vehicle (TCM; black circle) or synthetic AMCP (red circle) or with bacterial
peptidoglycan (gray circle). Positive control crude peptidoglycan shown in open gray circles. **P b 0.01 and ***P b 0.001 versus vehicle (n = 6). (B) Cell viability
was assessed by flow cytometry in monocytes (white column, n = 5 ± SD) and by the LDH assay in THP1 cells (red column, duplicates). ***P = 0.0003 versus
AMCP (red column). (C) Average log2 expression values of genes, after 3 h exposure to syntheticAMCP, correlated against those of vehicle control treatment (n = 7).
(D) Average log2 fold changes of genes significantly affected (P b 0.01, n = 7) by 3 h treatment with synthetic AMCP/sPg nanoparticles or with sPg alone (both
versus vehicle control) and plotted against each other. Theoretical line of perfect correlation (black line) and borders corresponding to twofold up- and down-regulation
(red lines) were overlaid on the data in both c and d.
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precisely the same (i.e., no gene regulation differed by more than
the ‘cut-off’ of 2-fold; Figure 6, D).
These findings also showed therefore that, PD-L1, the likely
target for peptidoglycan signaling in the AMCP nanomineral
pathway in vivo,17 was equally upregulated whether peptido-
glycan from E. coli was delivered alone or as cargo (Figure S3).
Given that peptidoglycan also derives from Gram+ bacteria, we
finally confirmed that peptidoglycan from Gram+S. aureus,
alone or delivered by the AMCP nanomineral, similarly
imprinted PD-L1 expression on APCs in in vitro cell culture
(Figure 7).
Together, our data demonstrate that in vitro synthetic AMCP
nanoparticles mimic their in vivo endogenous counterparts in terms
of size (Figure 8, A), elemental composition (Figure 8, B), and in
the trapping ofmacromolecules (cargo) allowing effective delivery
to cells (Figure 8, C). Moreover we show that the in vivo reported
biological function of PD-L1 up-regulation, driven by the
peptidoglycan cargo,17,33 is conserved in vitro (Figure 8, D).Discussion
Constitutive formation of AMCP nanoparticles, typically
75-150 nm in diameter, is a normal physiological and conservedprocess that occurs in the gastrointestinal tract of different
mammalian species.17 During its formation, the AMCP
nanomineral co-associates with macromolecules that are present
in the lumen and, like other non-biological particles of similar
sizes,34 efficiently crosses the epithelial barrier viaM cells of the
Peyer's patches.17 The cargo-containing nanomineral transiently
accumulates in APCs underlying the epithelium where mineral
digestion and release of the cargo occur.17 This process likely
promotes immuno-surveillance of luminal antigens. In this work,
we aimed to produce synthetic forms of these particles with a
view to start trying to establish some of their biological relevance
in in vitro investigations.
Our findings demonstrate that synthetic AMCP nanoparticles
act as effective but entirely silent delivery platforms both in their
own right and also in terms of cellular responses to peptidogly-
can. For two reasons these findings are surprising. Firstly, while
failure to activate the inflammasome by apatitic calcium
phosphate nanoparticles has been reported recently by us, a
lack of cell death following gorging (i.e. up to 24 h exposure to
synthetic AMCP nanomineral) was unexpected based upon these
prior studies.30 It is possible that the cargo contained within the
AMCP confers protection against cell death by slowing down
lysosomal dissolution of the nanoparticles, as recently demon-
strated for fetuin and calcium phosphate in human vascular
smooth muscle cells,35 ensuring cell safety of the entire conjugate.
Figure 7. Peptidoglycan cargo of AMCP nanomineral upregulates cellular PD-L1 expression: (A) Cell surface PD-L1 is upregulated in antigen presenting cells
by peptidoglycan (Pg) and by Pg delivered in synthetic nanomineral particles (AMCP/Pg) that were visualized by pre-labeling with calcein. (B) Example flow
cytometric plots of CD11b+ pre-gated cells showing dual calcein/PD-L1 positivity upon stimulation with vehicle (control), peptidoglycan (Pg) or calcein-tagged
Pg-bearing synthetic nanomineral particles (AMCP/Pg). (C) Representative histograms showing PD-L1 positivity of CD11b+ gated cells following exposure to
protein-bearing synthetic nanomineral particles (AMCP), peptidoglycan (Pg) or Pg-bearing nanomineral particles (AMCP/Pg). (D) Mean ± SEM PD-L1+
CD11b+ cells within the monocyte gate of peripheral blood mononuclear cell populations derived from 7 healthy donors following exposure to protein-bearing
synthetic nanomineral particles (AMCP), peptidoglycan (Pg) or Pg-bearing synthetic nanomineral particles (AMCP/Pg). * Asterisked data are not significantly
different while P b 10−6 for asterisked versus non-asterisked data.
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phosphates, have been widely used as adjuvants to enhance
immunogenicity to protein antigens and microbial associated
molecular patterns,36–38 again unlike the role of the particles in this
study. The anticipated in vivo function of endogenously-formed
AMCP may require this inert (silent-delivery) nature of the
cargo-bearing particles because the default setting for gastrointes-
tinal immune cells is one of hyporesponsiveness and tolerance
towards non-self antigens.39,40 While the AMCP is inert, its cargo
(notably peptidoglycan) appears to actively promote tolerance in
the normal gut by up-regulating the co-regulatory molecule,
PD-L1, on APCs that are recipients of endogenous cargo-bearing
AMCP.17,33 However, this is not the case in Crohn's disease.41We
have recently shown that APCs of the AMCP pathway display a
selective failure in expression of PD-L1 in this disorder41 andhence hypothesized that this may lead to a loss of tolerance towards
luminal contents—a hallmark of the disease.42 It is therefore likely
that, under normal circumstances, the mammalian gut immune
system has evolved to use an endogenous carrier of luminal
macromolecules that can (a) trap luminal proteins and microbial
associated molecular patterns effectively, (b) allow transport to
APCs while protecting the cargo from enzymatic degradation en
route and, pertinent to the findings here, (c) not promote cellular
reactivity in a naturally hyporesponsive environment.
In summary, the synthesis of AMCP has been inspired by its
presence in nature and it may be a rather special nanomaterial
that does not, acutely, promote cell activity following its uptake
nor shield the cell signaling of its cargo. Further work should
now consider AMCP for the delivery of immunogenic protein
(with and without bacterial fragments) and see how this might
Figure 8. Comparisons of in vitro synthetic AMCP to the in vivo AMCP nanomineral.The upper panel displays the in vivo characteristics of AMCP and has been
reproduced with permission from Nature Nanotechnology (adapted from Powell JJ et al17). The lower panel is a summary of the characteristics of in vitro
generated AMCP in this work. (A) High angle annular dark-field STEM image of AMCP particle clusters. (B) Elemental composition by energy dispersive
X-ray microanalysis. (C-D) Upper panels: (C) In vivo confocal micrographs showing a 3D stack, with Huygens MLE deconvolution, visualized with calcein
staining for the endogenous nanomineral (green) and with antibody staining for ovalbumin (red) and (D) PD-L1 (red) expression in calcein positive (green) cells.
(C-D) The lower panels displays the in vitro equivalence and shows the percentage of fluorescent protein (red column for BSA555 and red dashed column for
Texas Red OVA) present within AMCP, the uptake of synthetic AMCP (green) into PD-L1+ cells (yellow) by Image Stream and the resulting PD-L1
up-regulation (green histogram) by Flow cytometry.
629L.C. Pele et al / Nanomedicine: Nanotechnology, Biology, and Medicine 13 (2017) 619–630influence cell mediated immunity. This would further inform on
function and perhaps provide a novel therapeutic nano-carrier,
especially for impacting tolerance in the gut.
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